Bacteriophages

CCHEMISTRY METALLURGY C12Biochemistry C12NMICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA

C12N2795/00Bacteriophages

C12N2795/00011Bacteriophages C12N2795/00021Viruses as such C12N2795/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/00023Virus like particles [VLP] C12N2795/00031Uses of virus other than therapeutic or vaccine C12N2795/00032Use of virus as therapeutic agent, other than vaccine C12N2795/00033Use of viral protein as therapeutic agent other than vaccine C12N2795/00034Use of virus or viral component as vaccine C12N2795/00041Use of virus, viral particle or viral elements as a vector C12N2795/00042virus or viral particle as vehicle C12N2795/00043viral genome or elements thereof as genetic vector C12N2795/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/00045Special targeting system for viral vectors C12N2795/00051Methods of production or purification of viral material C12N2795/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/00061Methods of inactivation or attenuation C12N2795/00062by genetic engineering C12N2795/00063by chemical treatment C12N2795/00064by serial passage C12N2795/00071Demonstrated in vivo effect C12N2795/00088For redistribution C12N2795/10011dsDNA Bacteriophages C12N2795/10021Viruses as such C12N2795/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/10023Virus like particles [VLP] C12N2795/10031Uses of virus other than therapeutic or vaccine C12N2795/10032Use of virus as therapeutic agent, other than vaccine C12N2795/10033Use of viral protein as therapeutic agent other than vaccine C12N2795/10034Use of virus or viral component as vaccine C12N2795/10041Use of virus, viral particle or viral elements as a vector C12N2795/10042virus or viral particle as vehicle C12N2795/10043viral genome or elements thereof as genetic vector C12N2795/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/10045Special targeting system for viral vectors C12N2795/10051Methods of production or purification of viral material C12N2795/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/10061Methods of inactivation or attenuation C12N2795/10062by genetic engineering C12N2795/10063by chemical treatment C12N2795/10064by serial passage C12N2795/10071Demonstrated in vivo effect C12N2795/10088For redistribution C12N2795/10111Myoviridae C12N2795/10121Viruses as such C12N2795/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/10123Virus like particles [VLP] C12N2795/10131Uses of virus other than therapeutic or vaccine C12N2795/10132Use of virus as therapeutic agent, other than vaccine C12N2795/10133Use of viral protein as therapeutic agent other than vaccine C12N2795/10134Use of virus or viral component as vaccine C12N2795/10141Use of virus, viral particle or viral elements as a vector C12N2795/10142virus or viral particle as vehicle C12N2795/10143viral genome or elements thereof as genetic vector C12N2795/10144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/10145Special targeting system for viral vectors C12N2795/10151Methods of production or purification of viral material C12N2795/10152relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/10161Methods of inactivation or attenuation C12N2795/10162by genetic engineering C12N2795/10163by chemical treatment C12N2795/10164by serial passage C12N2795/10171Demonstrated in vivo effect C12N2795/10188For redistribution C12N2795/10211Podoviridae C12N2795/10221Viruses as such C12N2795/10222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/10223Virus like particles [VLP] C12N2795/10231Uses of virus other than therapeutic or vaccine C12N2795/10232Use of virus as therapeutic agent, other than vaccine C12N2795/10233Use of viral protein as therapeutic agent other than vaccine C12N2795/10234Use of virus or viral component as vaccine C12N2795/10241Use of virus, viral particle or viral elements as a vector C12N2795/10242virus or viral particle as vehicle C12N2795/10243viral genome or elements thereof as genetic vector C12N2795/10244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/10245Special targeting system for viral vectors C12N2795/10251Methods of production or purification of viral material C12N2795/10252relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/10261Methods of inactivation or attenuation C12N2795/10262by genetic engineering C12N2795/10263by chemical treatment C12N2795/10264by serial passage C12N2795/10271Demonstrated in vivo effect C12N2795/10288For redistribution C12N2795/10311Siphoviridae C12N2795/10321Viruses as such C12N2795/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/10323Virus like particles [VLP] C12N2795/10331Uses of virus other than therapeutic or vaccine C12N2795/10332Use of virus as therapeutic agent, other than vaccine C12N2795/10333Use of viral protein as therapeutic agent other than vaccine C12N2795/10334Use of virus or viral component as vaccine C12N2795/10341Use of virus, viral particle or viral elements as a vector C12N2795/10342virus or viral particle as vehicle C12N2795/10343viral genome or elements thereof as genetic vector C12N2795/10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/10345Special targeting system for viral vectors C12N2795/10351Methods of production or purification of viral material C12N2795/10352relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/10361Methods of inactivation or attenuation C12N2795/10362by genetic engineering C12N2795/10363by chemical treatment C12N2795/10364by serial passage C12N2795/10371Demonstrated in vivo effect C12N2795/10388For redistribution C12N2795/12011dsRNA Bacteriophages C12N2795/12021Viruses as such C12N2795/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/12023Virus like particles [VLP] C12N2795/12031Uses of virus other than therapeutic or vaccine C12N2795/12032Use of virus as therapeutic agent, other than vaccine C12N2795/12033Use of viral protein as therapeutic agent other than vaccine C12N2795/12034Use of virus or viral component as vaccine C12N2795/12041Use of virus, viral particle or viral elements as a vector C12N2795/12042virus or viral particle as vehicle C12N2795/12043viral genome or elements thereof as genetic vector C12N2795/12044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/12045Special targeting system for viral vectors C12N2795/12051Methods of production or purification of viral material C12N2795/12052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/12061Methods of inactivation or attenuation C12N2795/12062by genetic engineering C12N2795/12063by chemical treatment C12N2795/12064by serial passage C12N2795/12071Demonstrated in vivo effect C12N2795/12088For redistribution C12N2795/14011ssDNA Bacteriophages C12N2795/14021Viruses as such C12N2795/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/14023Virus like particles [VLP] C12N2795/14031Uses of virus other than therapeutic or vaccine C12N2795/14032Use of virus as therapeutic agent, other than vaccine C12N2795/14033Use of viral protein as therapeutic agent other than vaccine C12N2795/14034Use of virus or viral component as vaccine C12N2795/14041Use of virus, viral particle or viral elements as a vector C12N2795/14042virus or viral particle as vehicle C12N2795/14043viral genome or elements thereof as genetic vector C12N2795/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/14045Special targeting system for viral vectors C12N2795/14051Methods of production or purification of viral material C12N2795/14052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/14061Methods of inactivation or attenuation C12N2795/14062by genetic engineering C12N2795/14063by chemical treatment C12N2795/14064by serial passage C12N2795/14071Demonstrated in vivo effect C12N2795/14088For redistribution C12N2795/14111Inoviridae C12N2795/14121Viruses as such C12N2795/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/14123Virus like particles [VLP] C12N2795/14131Uses of virus other than therapeutic or vaccine C12N2795/14132Use of virus as therapeutic agent, other than vaccine C12N2795/14133Use of viral protein as therapeutic agent other than vaccine C12N2795/14134Use of virus or viral component as vaccine C12N2795/14141Use of virus, viral particle or viral elements as a vector C12N2795/14142virus or viral particle as vehicle C12N2795/14143viral genome or elements thereof as genetic vector C12N2795/14144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/14145Special targeting system for viral vectors C12N2795/14151Methods of production or purification of viral material C12N2795/14152relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/14161Methods of inactivation or attenuation C12N2795/14162by genetic engineering C12N2795/14163by chemical treatment C12N2795/14164by serial passage C12N2795/14171Demonstrated in vivo effect C12N2795/14188For redistribution C12N2795/14211Microviridae C12N2795/14221Viruses as such C12N2795/14222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/14223Virus like particles [VLP] C12N2795/14231Uses of virus other than therapeutic or vaccine C12N2795/14232Use of virus as therapeutic agent, other than vaccine C12N2795/14233Use of viral protein as therapeutic agent other than vaccine C12N2795/14234Use of virus or viral component as vaccine C12N2795/14241Use of virus, viral particle or viral elements as a vector C12N2795/14242virus or viral particle as vehicle C12N2795/14243viral genome or elements thereof as genetic vector C12N2795/14244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/14245Special targeting system for viral vectors C12N2795/14251Methods of production or purification of viral material C12N2795/14252relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/14261Methods of inactivation or attenuation C12N2795/14262by genetic engineering C12N2795/14263by chemical treatment C12N2795/14264by serial passage C12N2795/14271Demonstrated in vivo effect C12N2795/14288For redistribution C12N2795/16011ssRNA Bacteriophages negative-sense C12N2795/16021Viruses as such C12N2795/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/16023Virus like particles [VLP] C12N2795/16031Uses of virus other than therapeutic or vaccine C12N2795/16032Use of virus as therapeutic agent, other than vaccine C12N2795/16033Use of viral protein as therapeutic agent other than vaccine C12N2795/16034Use of virus or viral component as vaccine C12N2795/16041Use of virus, viral particle or viral elements as a vector C12N2795/16042virus or viral particle as vehicle C12N2795/16043viral genome or elements thereof as genetic vector C12N2795/16044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/16045Special targeting system for viral vectors C12N2795/16051Methods of production or purification of viral material C12N2795/16052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/16061Methods of inactivation or attenuation C12N2795/16062by genetic engineering C12N2795/16063by chemical treatment C12N2795/16064by serial passage C12N2795/16071Demonstrated in vivo effect C12N2795/16088For redistribution C12N2795/18011ssRNA Bacteriophages positive-sense C12N2795/18021Viruses as such C12N2795/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/18023Virus like particles [VLP] C12N2795/18031Uses of virus other than therapeutic or vaccine C12N2795/18032Use of virus as therapeutic agent, other than vaccine C12N2795/18033Use of viral protein as therapeutic agent other than vaccine C12N2795/18034Use of virus or viral component as vaccine C12N2795/18041Use of virus, viral particle or viral elements as a vector C12N2795/18042virus or viral particle as vehicle C12N2795/18043viral genome or elements thereof as genetic vector C12N2795/18044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/18045Special targeting system for viral vectors C12N2795/18051Methods of production or purification of viral material C12N2795/18052relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/18061Methods of inactivation or attenuation C12N2795/18062by genetic engineering C12N2795/18063by chemical treatment C12N2795/18064by serial passage C12N2795/18071Demonstrated in vivo effect C12N2795/18088For redistribution C12N2795/18111Leviviridae C12N2795/18121Viruses as such C12N2795/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2795/18123Virus like particles [VLP] C12N2795/18131Uses of virus other than therapeutic or vaccine C12N2795/18132Use of virus as therapeutic agent, other than vaccine C12N2795/18133Use of viral protein as therapeutic agent other than vaccine C12N2795/18134Use of virus or viral component as vaccine C12N2795/18141Use of virus, viral particle or viral elements as a vector C12N2795/18142virus or viral particle as vehicle C12N2795/18143viral genome or elements thereof as genetic vector C12N2795/18144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2795/18145Special targeting system for viral vectors C12N2795/18151Methods of production or purification of viral material C12N2795/18152relating to complementing cells and packaging systems for producing virus or viral particles C12N2795/18161Methods of inactivation or attenuation C12N2795/18162by genetic engineering C12N2795/18163by chemical treatment C12N2795/18164by serial passage C12N2795/18171Demonstrated in vivo effect C12N2795/18188For redistribution